Merck & Company Inc
- Branche
- Pharmaceuticals
- Börse
- USA
- Land / Region
- USA
- Börsengang
- 13. Januar 1978
- Mitarbeiter
- 73.000
- Website
- www.merck.com
Zusammengesetzter Bewertungsbereich · konservativ $80–$95 / fair $100–$120 / optimistisch $125–$145. Bei $130.76, Innerhalb des optimistischen Bereichs des inneren Werts · viele Erwartungen eingepreist.
Bei Veröffentlichung $122.41 (25. Mai 2026)
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Geschichte
Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. The company's IPO date is January 13, 1978. It operates as a global healthcare company through two reporting segments, Pharmaceutical and Animal Health. In 2025 it generated total sales of $65.011 billion, with Pharmaceutical contributing $58.142 billion and Animal Health $6.354 billion, and it employs about 73,000 people.
Branchenposition
Merck is a global pharmaceutical, vaccine and animal-health company in the Drug Manufacturers - General industry. In 2025 its oncology drug Keytruda/Keytruda Qlex generated $31.680 billion in sales, accounting for 49% of total sales, while Gardasil/Gardasil 9 contributed $5.233 billion and Animal Health $6.354 billion. Within its U.S. distribution channel, McKesson, Cencora and Cardinal Health accounted for roughly 22%, 21% and 13% of accounts receivable at year-end 2025. The company maintains development and commercialization collaborations with partners including Daiichi Sankyo, AstraZeneca, Eisai, Bayer, Moderna and LaNova.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.